Scholars@Duke
Search form
Search
Advanced Search
Support
Index
Subscribe to Announcements
Menu
Search
Home
People
Schools / Institutes
Research
About
Home
People
Schools / Institutes
Research
Phase III study of ACP-196 vs Ibrutinib in High Risk CLL
Administered By
Duke Cancer Institute
Awarded By
Acerta Pharma
Contributors
Brander, Danielle Marie
Principal Investigator
Start/End
June 1, 2016 - May 31, 2022